BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Type 1 diabetes clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for type 1 diabetes: 158 (103 sponsors; 37 newly posted in the last 180 days, 2 stopped in the last 180 days; 23 new-entrant sponsors). Momentum score 20.6, rank 27 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 2, Phase 1 36, Phase 2 33, Phase 3 21, Phase 4 2, N/A 64.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Eli Lilly and Company LLY9P1 4, P3 522
Novo Nordisk A/S NVO9P1 4, P3 3, NA 222
AstraZeneca AZN5P3 3, P1 1, NA 131
Vertex Pharmaceuticals Incorporated VERX3P3 2, P2 101
Biocad2P3 201
Viking Therapeutics, Inc. VKTX2P3 210
Sanofi SNY9P2 3, NA 5, P3 103
vTv Therapeutics VTVT2P2 1, P3 111
Oramed, Ltd. ORMP1P3 101
Yong Zhao, MD, PhD1P3 100
Insulet Corporation PODD5NA 502
Medtronic MiniMed, Inc. MDT5NA 512
Helmholtz Zentrum München3NA 300
MedImmune LLC3P1 2, P2 100
Senseonics, Inc. SENS3NA 300
Amgen AMGN2P1 200
Arrowhead Pharmaceuticals ARWR2P2 201
Beta Bionics, Inc. BBNX2NA 210
Encellin2P1 210
GentiBio, Inc2NA 1, P1 101
Kriya Therapeutics, Inc. new entrant2P2 220
mylife Diabetes Care AG2NA 211
Renalytix AI, Inc. RNLXY2NA 200
Abbott Diabetes Care new entrant1NA 110
AC Immune SA ACIU1P1 101

New-entrant sponsors: Kriya Therapeutics, Inc., Abbott Diabetes Care.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Zucara Therapeutics Inc.NCT05762107 A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 DiabetesType 1 Diabetes Mellitus With Hypoglycemiarecruiting186
2027-01-31 est.P1/P2Creative Medical Technology Holdings Inc CELZNCT05626712 Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 DiabetesType 1 Diabetes; Diabetes Mellitus, Type 1recruiting18

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P3Eli Lilly and Company LLYNCT06962280 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightType 1 Diabetes; Obesity; Overweightactive not recruiting465
2026-11 est.P3Eli Lilly and Company LLYNCT06914895 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightType 1 Diabetes; Obesity; Overweightactive not recruiting905
2026-10 est.P1/P2Sernova Biotherapeutics Inc.NCT03513939 A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet TransplantationType 1 Diabetes Mellitusactive not recruiting17
2026-09-17 est.P3Vertex Pharmaceuticals Incorporated VERXNCT06832410 An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney TransplantType 1 Diabetes; Kidney Transplantrecruiting10
2026-06-24P3Diamyd Medical ABNCT05018585 A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 DType 1 Diabetes Mellitusterminated321

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "type 1 diabetes"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.